State Street’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

State Street’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-246,853	Closed	-$3.65M	–	4464
2024 Q1	$3.65M	Buy	246,853 +50,148	+25%	+$705K	﹤0.01%	3054
2023 Q4	$2.64M	Buy	196,705 +4,861	+3%	+$61.4K	﹤0.01%	3223
2023 Q3	$2.37M	Buy	191,844 +17,739	+10%	+$215K	﹤0.01%	3261
2023 Q2	$2.14M	Buy	174,105 +123,549	+244%	+$1.54M	﹤0.01%	3382
2023 Q1	$621K	Buy	50,556 +1,700	+3%	+$20K	﹤0.01%	3671
2022 Q4	$560K	Buy	48,856 +2,300	+5%	+$18.9K	﹤0.01%	3733
2022 Q3	$175K	Hold	46,556	–	–	﹤0.01%	4211
2022 Q2	$277K	Hold	46,556	–	–	﹤0.01%	4067
2022 Q1	$294K	Hold	46,556	–	–	﹤0.01%	4246
2021 Q4	$182K	Hold	46,556	–	–	﹤0.01%	4387
2021 Q3	$225K	Hold	46,556	–	–	﹤0.01%	4316
2021 Q2	$297K	Buy	46,556 +35,371	+316%	+$233K	﹤0.01%	4056
2021 Q1	$70K	Hold	11,185	–	–	﹤0.01%	3925
2020 Q4	$77K	Hold	11,185	–	–	﹤0.01%	3822
2020 Q3	$45K	Hold	11,185	–	–	﹤0.01%	3764
2020 Q2	$37K	Hold	11,185	–	–	﹤0.01%	3730
2020 Q1	$24K	Hold	11,185	–	–	﹤0.01%	3694
2019 Q4	$35K	Hold	11,185	–	–	﹤0.01%	3744
2019 Q3	$50K	Sell	11,185 -3,031	-21%	-$15.1K	﹤0.01%	3721
2019 Q2	$68K	Hold	14,216	–	–	﹤0.01%	3703
2019 Q1	$78K	Hold	14,216	–	–	﹤0.01%	3656
2018 Q4	$43K	Sell	14,216 -12,422	-47%	-$43.1K	﹤0.01%	3689
2018 Q3	$112K	Buy	26,638 +1,296	+5%	+$5.46K	﹤0.01%	3643
2018 Q2	$98K	Sell	25,342 -252,239	-91%	-$1.67M	﹤0.01%	3633
2018 Q1	$1.76M	Sell	277,581 -1,613	-0.6%	-$13.3K	﹤0.01%	3210
2017 Q4	$2.25M	Sell	279,194 -6,790	-2%	-$63.3K	﹤0.01%	3144
2017 Q3	$3.27M	Buy	285,984 +138	+0%	+$1.45K	﹤0.01%	2988
2017 Q2	$2.79M	Sell	285,846 -554,441	-66%	-$11.3M	﹤0.01%	3000
2017 Q1	$20.4M	Buy	840,287 +160,372	+24%	+$4.01M	﹤0.01%	1934
2016 Q4	$21.8M	Buy	679,915 +96,170	+16%	+$4.1M	﹤0.01%	1835
2016 Q3	$29.2M	Buy	583,745 +86,953	+18%	+$3.61M	﹤0.01%	1516
2016 Q2	$21.1M	Buy	496,792 +119,446	+32%	+$6.51M	﹤0.01%	1715
2016 Q1	$24.9M	Sell	377,346 -58,743	-13%	-$3.07M	﹤0.01%	1571
2015 Q4	$27.1M	Sell	436,089 -77,914	-15%	-$5.48M	﹤0.01%	1502
2015 Q3	$34.4M	Buy	514,003 +7,496	+1%	+$612K	﹤0.01%	1379
2015 Q2	$49.3M	Buy	506,507 +66,051	+15%	+$6.29M	0.01%	1276
2015 Q1	$41.2M	Buy	440,456 +32,668	+8%	+$2.78M	﹤0.01%	1358
2014 Q4	$36.3M	Sell	407,788 -58,942	-13%	-$4.29M	﹤0.01%	1391
2014 Q3	$32.2M	Buy	466,730 +34,682	+8%	+$1.85M	﹤0.01%	1407
2014 Q2	$24.8M	Sell	432,048 -157,902	-27%	-$8.02M	﹤0.01%	1664
2014 Q1	$23.4M	Buy	589,950 +404,578	+218%	+$17.3M	﹤0.01%	1659
2013 Q4	$7.79M	Buy	185,372 +24,301	+15%	+$704K	﹤0.01%	2319
2013 Q3	$4.82M	Buy	161,071 +12,738	+9%	+$446K	﹤0.01%	2556
2013 Q2	$7.86M	Buy	+148,333	New	+$6.5M	﹤0.01%	2197

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street's MACK Position: Q2 2024 in Review

State Street sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 246,853 shares — an estimated $3.65M sold.

State Street first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $49.3M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

State Street reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
State Street sold 246,853 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $3.65M.
State Street first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
State Street's Merrimack Pharmaceuticals, Inc. position peaked at $49.3M in Q2 2015.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.